Michael Thomas

32.3k total citations · 6 hit papers
359 papers, 12.6k citations indexed

About

Michael Thomas is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Michael Thomas has authored 359 papers receiving a total of 12.6k indexed citations (citations by other indexed papers that have themselves been cited), including 241 papers in Pulmonary and Respiratory Medicine, 213 papers in Oncology and 69 papers in Cancer Research. Recurrent topics in Michael Thomas's work include Lung Cancer Treatments and Mutations (195 papers), Lung Cancer Research Studies (101 papers) and Lung Cancer Diagnosis and Treatment (88 papers). Michael Thomas is often cited by papers focused on Lung Cancer Treatments and Mutations (195 papers), Lung Cancer Research Studies (101 papers) and Lung Cancer Diagnosis and Treatment (88 papers). Michael Thomas collaborates with scholars based in Germany, United States and Italy. Michael Thomas's co-authors include Wolfgang E. Berdel, Carsten Müller‐Tidow, Sven Diederichs, Hubert Serve, Thomas Muley, Paul M. Schneider, Burkhard Brandt, Etmar Bulk, Ralf Metzger and Ping Ji and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Michael Thomas

342 papers receiving 12.4k citations

Hit Papers

MALAT-1, a novel noncoding RNA, and thymosin β4 predict m... 2003 2026 2010 2018 2003 2012 2017 2012 2013 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. MALAT-1, a novel noncoding RNA, and thymosin β4 predict metastasis and survival in early-stage non-small cell lung cancer
    2003 1.8k citations Ping Ji, Sven Diederichs et al. profile →
  2. The Novel Histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification System of Lung Adenocarcinoma Is a Stage-Independent Predictor of Survival
    2012 542 citations Arne Warth, Thomas Muley et al. Journal of Clinical Oncology profile →
  3. Early palliative care for adults with advanced cancer
    2017 479 citations Matthias Villalobos, Michael Thomas et al. profile →
  4. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial
    2012 447 citations Luis Paz‐Ares, Michael Thomas et al. profile →
  5. PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer
    2013 438 citations Luis Paz‐Ares, Michael Thomas et al. Journal of Clinical Oncology profile →
  6. When do we need to care about the caregiver? Supportive care needs, anxiety, and depression among informal caregivers of patients with cancer and cancer survivors
    2015 311 citations Michael Thomas et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Thomas Germany 50 6.6k 5.9k 4.0k 3.5k 1.1k 359 12.6k
Rebecca S. Heist United States 51 6.1k 0.9× 6.2k 1.1× 4.3k 1.1× 2.2k 0.6× 726 0.7× 268 11.6k
Patrick Neven Belgium 57 5.0k 0.8× 8.6k 1.5× 2.8k 0.7× 4.5k 1.3× 1.0k 1.0× 493 15.7k
Bella Kaufman Israel 54 3.7k 0.6× 8.1k 1.4× 4.4k 1.1× 3.2k 0.9× 1.3k 1.3× 250 15.2k
Karen Kelly United States 59 8.3k 1.3× 9.4k 1.6× 3.4k 0.8× 1.7k 0.5× 767 0.7× 390 14.8k
Otis W. Brawley United States 34 3.6k 0.5× 5.1k 0.9× 2.3k 0.6× 1.8k 0.5× 875 0.8× 61 11.5k
Kathy S. Albain United States 61 9.2k 1.4× 11.9k 2.0× 2.9k 0.7× 3.8k 1.1× 2.1k 2.0× 234 19.1k
Dino Amadori Italy 60 3.1k 0.5× 6.7k 1.1× 4.5k 1.1× 4.3k 1.2× 999 0.9× 351 14.2k
Cesare Gridelli Italy 55 7.3k 1.1× 7.7k 1.3× 3.1k 0.8× 1.7k 0.5× 491 0.5× 413 12.6k
Kwun M. Fong Australia 56 6.2k 0.9× 4.4k 0.7× 6.1k 1.5× 2.5k 0.7× 683 0.6× 236 12.9k
Susan Halabi United States 61 10.0k 1.5× 6.6k 1.1× 3.9k 1.0× 4.8k 1.4× 2.5k 2.3× 386 16.9k

Countries citing papers authored by Michael Thomas

Since Specialization
Citations

This map shows the geographic impact of Michael Thomas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Thomas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Thomas more than expected).

Fields of papers citing papers by Michael Thomas

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Thomas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Thomas. The network helps show where Michael Thomas may publish in the future.

Co-authorship network of co-authors of Michael Thomas

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Thomas. A scholar is included among the top collaborators of Michael Thomas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Thomas. Michael Thomas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Thomas, Michael, Thomas Schmidt, Christian Krautz, et al.. (2025). Bots in white coats: are large language models the future of patient education? A multicenter cross-sectional analysis. International Journal of Surgery. 111(3). 2376–2384. 4 indexed citations
2.
Sebastian, Martin, Wilfried Eberhardt, Steffen Dörfel, et al.. (2024). Patient‐reported outcomes in advanced NSCLC before and during the COVID‐19 pandemic: Real‐world data from the German prospective CRISP Registry (AIO‐TRK‐0315). International Journal of Cancer. 154(11). 1967–1978.
3.
Shah, Rajiv, Martin Reck, Christian Grohé, et al.. (2024). Efficacy of nivolumab/ipilimumab as first-line treatment of pleural mesothelioma in the German real-world setting.. Journal of Clinical Oncology. 42(16_suppl). 8085–8085. 1 indexed citations
4.
5.
Donaldson, David, et al.. (2023). Phosphorus adsorption and organic release from dried and thermally treated water treatment sludge. Environmental Research. 234. 116524–116524. 8 indexed citations
6.
Baghbani, Abolfazl, Ali Alnedawi, Bidur Kafle, et al.. (2023). Experimental Study on the Suitability of Aluminium-Based Water Treatment Sludge as a Next Generation Sustainable Soil Replacement for Road Construction. SSRN Electronic Journal. 8 indexed citations
7.
Walter, Julia, Diego Kauffmann‐Guerrero, Thomas Muley, et al.. (2023). Comparison of the sensitivity of different criteria to select lung cancer patients for screening in a cohort of German patients. Cancer Medicine. 12(7). 8880–8896. 2 indexed citations
8.
Shah, Rajiv, Laura V. Klotz, Daniel C. Christoph, et al.. (2023). Nivolumab with chemotherapy in pleural mesothelioma after surgery: The NICITA trial.. Journal of Clinical Oncology. 41(16_suppl). TPS8601–TPS8601. 1 indexed citations
9.
Garon, Edward B., Shun Lü, Yasushi Goto, et al.. (2023). Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non–Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical Trial. Journal of Clinical Oncology. 42(2). 180–191. 41 indexed citations
10.
Christopoulos, Petros, Richard F. Schlenk, Daniel Kazdal, et al.. (2023). Real‐world data for precision cancer medicine—A European perspective. Genes Chromosomes and Cancer. 62(9). 557–563. 9 indexed citations
11.
12.
Baum, Philip, Thomas Muley, Mark Kriegsmann, et al.. (2021). Validation of the T Descriptor (TNM-8) in T3N0 Non-Small-Cell Lung Cancer Patients; a Bicentric Cohort Analysis with Arguments for Redefinition. Cancers. 13(8). 1812–1812. 1 indexed citations
13.
Aigner, Clemens, Thomas Brüning, Wilfried Eberhardt, et al.. (2021). Die aktuelle Therapie des asbestassoziierten malignen Pleuramesothelioms – Ein Experten-Konsensuspapier. Pneumologie. 75(10). 776–794. 1 indexed citations
14.
Schuette, Wolfgang, Peter Schirmacher, Wilfried Eberhardt, et al.. (2018). Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study. BMC Cancer. 18(1). 135–135. 10 indexed citations
15.
Christopoulos, Petros, Volker Endris, Farastuk Bozorgmehr, et al.. (2018). EML4‐ALK fusion variant V3 is a high‐risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK+ non‐small cell lung cancer. International Journal of Cancer. 142(12). 2589–2598. 79 indexed citations
16.
Schneider, Marc A., Martin Granzow, Arne Warth, et al.. (2015). Glycodelin: A New Biomarker with Immunomodulatory Functions in Non–Small Cell Lung Cancer. Clinical Cancer Research. 21(15). 3529–3540. 45 indexed citations
17.
Schuette, Wolfgang, Peter Schirmacher, Wilfried Eberhardt, et al.. (2015). EGFR Mutation Status and First-Line Treatment in Patients with Stage III/IV Non–Small Cell Lung Cancer in Germany: An Observational Study. Cancer Epidemiology Biomarkers & Prevention. 24(8). 1254–1261. 29 indexed citations
18.
Warth, Arne, Thomas Muley, Michael Meister, et al.. (2012). The Novel Histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification System of Lung Adenocarcinoma Is a Stage-Independent Predictor of Survival. Journal of Clinical Oncology. 30(13). 1438–1446. 542 indexed citations breakdown →
19.
Diederichs, Sven, Etmar Bulk, Björn Steffen, et al.. (2004). S100 Family Members and Trypsinogens Are Predictors of Distant Metastasis and Survival in Early-Stage Non-Small Cell Lung Cancer. Cancer Research. 64(16). 5564–5569. 168 indexed citations
20.
Eberhardt, Wilfried, Kathy S. Albain, Harvey I. Pass, et al.. (2003). Induction treatment before surgery for non-small cell lung cancer. Lung Cancer. 42(2). 9–14. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rebecca S. Heist Breakdown of academic impact, for papers by Patrick Neven Breakdown of academic impact, for papers by Bella Kaufman Breakdown of academic impact, for papers by Karen Kelly Breakdown of academic impact, for papers by Otis W. Brawley Breakdown of academic impact, for papers by Kathy S. Albain Breakdown of academic impact, for papers by Dino Amadori Breakdown of academic impact, for papers by Cesare Gridelli Breakdown of academic impact, for papers by Kwun M. Fong Breakdown of academic impact, for papers by Susan Halabi
Rankless by CCL
2026